Cerebrospinal fluid levels of sphingolipids associate with disease severity in first episode psychosis patients

Affiliations

• ¹ Division of Physiological Chemistry II, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-171 77 Stockholm, Sweden.
• ² Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm, Sweden.
• ³ Department of Clinical Neuroscience, Center for Psychiatry Research, Karolinska Institutet and Stockholm County Council, Stockholm, Sweden.
• ⁴ Center for Social and Affective Neuroscience, Department of Clinical and Experimental Medicine, Faculty of Health Sciences, Linköping University, Linköping, Sweden; Department of Psychiatry, Local Health Care Services in Central Östergötland, Region Östergötland, Linköping, Sweden.
• ⁵ Department of Laboratory Medicine, Division of Clinical Pharmacology, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden.
• ⁶ Department of Clinical Neurosciences, Section of Neurology, Karolinska Institutet, Stockholm, Sweden.
• ⁷ Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, & Stockholm County Council, Stockholm, Sweden.
• ⁸ Neuroimmunology Unit, Department of Clinical Neuroscience, Karolinska Institutet, Stockholm, Sweden.
• ⁹ Centre for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet, & Stockholm County Council, Stockholm, Sweden; NORMENT, KG Jebsen Centre for Psychosis Research, Division of Mental Health and Addiction, University of Oslo, Oslo, Norway; Department of Psychiatry Research, Diakonhjemmet Hospital, Oslo, Norway.
• ¹⁰ Division of Physiological Chemistry II, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, SE-171 77 Stockholm, Sweden. Electronic address: [email protected].